LY2090314 supplier|LY-2090314|DC Chemicals

LY2090314 supplier|LY-2090314|DC Chemicals
DC Chemicals provides LY2090314, other names: LY 2090314，LY-2090314, cas: 603288-22-8. In stock.

Contact: website: www.dcchemicals.com,
sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,
Tel: +86-21-58447131;Fax:+86-21-61643274；

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively.

LY2090314, other names: LY 2090314，LY-2090314, cas: 603288-22-8, Molecule formular: C28H25FN6O3, Molecule Weight: 512.53, Chemical name: 3-(9-fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione

LY2090314 selectively inhibits the activity of GSK-3 by interrupting ATP binding. LY2090314 is able to stabilize β-catenin. LY2090314 shows limited efficacy as monotherapy. LY3090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer cell lines in vitro.
in vivo: Even in Mdr1a-, Bcrp-, and Mrp2-knockout rats, LY2090314 metabolites did not appear in circulation, and their urinary excretion was not enhanced, because the hypothesized impaired biliary excretion of metabolites in the absence of these canalicular transporters was not observed. Canine metabolite disposition was generally similar, with the notable exception of dog-unique LY2090314 glucuronide  For the detailed information of LY2090314, the solubility of LY2090314 in water, the solubility of LY2090314 in DMSO, the solubility of LY2090314 in PBS buffer, the animal experiment (test) of  LY2090314, the cell expriment (test) of LY2090314, the in vivo, in vitro and clinical trial test of LY2090314, the EC50, IC50,and affinity,of LY2090314, Please contact DC Chemicals.